Research letterTofacitinib for cutaneous and pulmonary sarcoidosis: A case series
References (5)
- et al.
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
J Am Acad Dermatol
(2020) - et al.
Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera
JAAD Case Rep
(2019)
Cited by (21)
Cutaneous Sarcoidosis
2024, Clinics in Chest MedicineAnti-inflammatory Therapy for Sarcoidosis
2024, Clinics in Chest MedicineQuality of life in sarcoidosis
2023, Journal of AutoimmunityThe CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells
2022, Journal of NeuroimmunologyCitation Excerpt :These findings suggests that IFNγ-driven JAK/STAT signaling may play a central pathogenic role across multiple tissues in sarcoidosis. In support of this, multiple case reports or small case series have described the successful treatment of cutaneous, pulmonary, or multiorgan sarcoidosis with the JAK inhibitor tofacitinib or baricitinib (Alam et al., 2021; Damsky et al., 2018; Damsky et al., 2020; Friedman et al., 2021; Kerkemeyer et al., 2021; Scheinberg et al., 2020; Singh et al., 2021; Talty et al., 2021). Thus, JAK inhibitors may offer an additional treatment option to the current set of therapeutics by targeting IFN-signaling.
Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib
2022, European Journal of Internal Medicine
Funding sources: None.
Disclosure: Dr Sinclair holds patent/intellectual property no. US 62811353 entitled “Treatment of Autoimmune Disease.” Drs Kerkemeyer and Meah have no conflicts of interest to declare.
IRB approval status: Not applicable: retrospective design, patients treated during routine clinical practice (and not as part of a study involving subjects).